Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Colombia’s President Embraces 'Hodler' Status, Banks on Country’s Future with Bitcoin and Blockchain
-
Markets Anxious As Oil Price Surge Spotlights Inflationary Fears
-
Bitcoin Primed for Gargantuan Rally Ahead Of 2024 Halving, Says Market Analyst
-
Ether Shines In Crypto Rally
-
$BTC: Legendary Investor Paul Tudor Jones Says He Has ‘Always’ Owned Some Bitcoin